While CCR2 inhibitors (such as RS504393) can alleviate general renal fibrosis, their effectiveness in NAFLD‐induced pathologies remains uncertain.[50, 51] In our NAFLD‐UUO model, CCR2 blockade significantly inhibited the abnormal expansion of CCR2+PIRB+ macrophages, reducing IL‐6 and IL‐23 levels, Th17 cell proliferation, and the severity of fibrosis. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatotic liver disease.